Sutimlimab Cad denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sutimlimab cad are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sutimlimab for Cold Agglutinin Disease — Medical Necessity

A medical necessity denial for sutimlimab in cold agglutinin disease (CAD) means BCBS has determined that the clinical documentation submitted does not sufficiently establish that the drug is required for this patient's condition at this time. CAD is a rare chronic hemolytic anemia driven by cold-reactive autoantibodies, and the clinical case for sutimlimab often depends on nuanced documentation of disease severity, transfusion burden, and the failure or inadequacy of prior management strategies. Gaps in that documentation are the most common reason these denials issue — and the most correctable.

## Why This Denial Is Appealable

Medical necessity denials are overturned at high rates when a thorough, well-organized appeal is submitted with complete clinical documentation. BCBS's medical necessity criteria for sutimlimab will reference the FDA-approved indication and typically mirror criteria derived from the prescribing label and applicable hematology guidelines. If your prescriber's records document the diagnosis, disease severity, prior treatment history, and the clinical rationale for sutimlimab, the factual basis for the denial can usually be dismantled point by point. Consult the FDA prescribing information and BCBS's published hematology coverage policy to identify every criterion and address each one explicitly.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the plan's deadline from the denial date (typically 180 days). Request the complete medical necessity criteria BCBS applied and identify each criterion not yet satisfied according to the denial letter.
• Peer-to-peer review: Request a peer-to-peer call between the treating hematologist and the BCBS medical reviewer before or during the internal appeal — this is often the fastest path to reversal.
• External review (ACA §2719): After a final internal denial, request independent external review within approximately four months. An IRO with relevant expertise will assess medical necessity independently.
• ERISA §503: Self-funded plan members may request the full administrative record.
• Expedited review: Request if clinical urgency (transfusion dependence, worsening hemolysis, hospitalization risk) is documented.

## Documentation to Gather

• Confirmed CAD diagnosis: cold agglutinin titer results, direct antiglobulin test (DAT) results, hemolytic markers from the chart
• Clinical severity documentation: symptom burden, fatigue impact, quality-of-life measures recorded in the chart
• Transfusion history: dates, number of units, clinical indications
• Prior treatment history: all prior agents or strategies used, with dates, duration, and documented response or failure
• Treating hematologist's comprehensive medical necessity letter referencing the FDA-approved indication and applicable guideline organization recommendations
• BCBS's published coverage policy for sutimlimab or complement inhibitors

## Criteria-Mapping Structure

Pull every criterion from BCBS's coverage policy. Create a two-column table: left column lists each policy requirement verbatim; right column cites the specific chart entry, lab result, or clinician statement that satisfies it. This structure forces the reviewer to engage with the evidence rather than issue a blanket denial. The hematologist's letter should close with a direct statement that the patient meets all stated criteria based on the documented clinical record.